Page last updated: 2024-10-26

famotidine and Pneumonia, Viral

famotidine has been researched along with Pneumonia, Viral in 8 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.

Research Excerpts

Excerpt	Relevance	Reference
"Famotidine was well tolerated."	1.56	Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. ( Conigliaro, J; Gablenz, E; Janowitz, T; Pattinson, D; Tracey, K; Tuveson, D; Wang, TC, 2020)

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	8 (100.00)	2.80

Authors

Authors	Studies
Freedberg, DE	1
Conigliaro, J	2
Wang, TC	2
Tracey, KJ	1
Callahan, MV	1
Abrams, JA	1
Janowitz, T	1
Gablenz, E	1
Pattinson, D	1
Tracey, K	1
Tuveson, D	1
Ortega, JT	1
Serrano, ML	1
Jastrzebska, B	1
Ghosh, R	1
Chatterjee, S	1
Dubey, S	1
Lavie, CJ	1
Mather, JF	1
Seip, RL	1
McKay, RG	1
Hogan Ii, RB	1
Hogan Iii, RB	1
Cannon, T	1
Rappai, M	1
Studdard, J	1
Paul, D	1
Dooley, TP	1
Grewal, E	1
Sutarjono, B	1
Mohammed, I	1
Samimagham, HR	1
Hassani Azad, M	1
Haddad, M	1
Arabi, M	1
Hooshyar, D	1
KazemiJahromi, M	1

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series[NCT04389567]		10 participants (Actual)	Observational	2020-05-12	Completed
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection[NCT06008860]	Phase 4	280 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262]	Phase 3	233 participants (Actual)	Interventional	2020-04-07	Completed
Evaluation of a Synbiotic Formula in Patient With COVID-19[NCT04730284]		20 participants (Anticipated)	Interventional	2020-08-25	Recruiting
A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19[NCT04724720]	Phase 2	56 participants (Actual)	Interventional	2021-01-19	Active, not recruiting
An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection[NCT04581018]		50 participants (Anticipated)	Interventional	2020-08-13	Enrolling by invitation
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients[NCT05077332]	Phase 2	2,000 participants (Anticipated)	Interventional	2021-12-29	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for famotidine and Pneumonia, Viral

Article	Year
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, Oct-13, Volume: 21, Issue:1 Topics: Betacoronavirus; Case-Control Studies; Clinical Protocols; Coronavirus Infections; COVID-19; Famotid	2020

Other Studies

7 other studies available for famotidine and Pneumonia, Viral

Article	Year
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 2020, Volume: 159, Issue:3 Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine;	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 2020, Volume: 69, Issue:9 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon	2020
Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis. Biomolecules, 2020, Jun-24, Volume: 10, Issue:6 Topics: Administration, Intravenous; Antiviral Agents; Computer Simulation; Coronavirus Infections; COVID-19	2020
Famotidine Against SARS-CoV2: A Hope or Hype? Mayo Clinic proceedings, 2020, Volume: 95, Issue:8 Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famoti	2020
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19. The American journal of gastroenterology, 2020, Volume: 115, Issue:10 Topics: Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment;	2020
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulmonary pharmacology & therapeutics, 2020, Volume: 63 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betacoronavirus; Cetirizine; Cohort Studies; Coronavirus	2020
Angioedema, ACE inhibitor and COVID-19. BMJ case reports, 2020, Sep-09, Volume: 13, Issue:9 Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Benzazepines; Betacorona	2020